使用肿瘤坏死因子α抑制剂治疗慢性、非感染性、非坏死性巩膜炎。
Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors.
作者信息
Ragam Ashwinee, Kolomeyer Anton M, Fang Christina, Xu Yinfei, Chu David S
机构信息
Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School , Newark, New Jersey , USA , and.
出版信息
Ocul Immunol Inflamm. 2014 Dec;22(6):469-77. doi: 10.3109/09273948.2013.863944. Epub 2013 Dec 19.
PURPOSE
To evaluate the use of TNF-alpha inhibitors for non-infectious, non-necrotizing scleritis.
METHODS
We conducted a retrospective chart review of patients with non-infectious, non-necrotizing scleritis treated at our institutions from 2002 to 2012.
RESULTS
Seventeen patients (26 eyes) were included. Ten patients were started on infliximab and seven on adalimumab; five patients were treated with both TNF-alpha inhibitors on separate occasions. All patients had an associated autoimmune disease. Control of active inflammation for at least 2 months was achieved in 15 (88%) of 17 patients. Seven out of eight patients successfully tapered concurrent corticosteroid use. Only one patient discontinued TNF-alpha inhibitor use due to an allergic reaction.
CONCLUSIONS
TNF-alpha inhibitors appear to have a role in managing non-infectious, non-necrotizing scleritis refractory to initial therapy, mainly by reducing inflammation and decreasing concurrent CS use.
目的
评估肿瘤坏死因子-α（TNF-α）抑制剂在非感染性、非坏死性巩膜炎治疗中的应用。
方法
我们对2002年至2012年在我们机构接受治疗的非感染性、非坏死性巩膜炎患者进行了回顾性病历审查。
结果
纳入17例患者（26只眼）。10例患者开始使用英夫利昔单抗，7例使用阿达木单抗；5例患者在不同时间接受了两种TNF-α抑制剂治疗。所有患者均患有相关的自身免疫性疾病。17例患者中有15例（88%）实现了至少2个月的活动性炎症控制。8例患者中有7例成功减少了同时使用的皮质类固醇剂量。只有1例患者因过敏反应停用TNF-α抑制剂。
结论
TNF-α抑制剂似乎在治疗初始治疗难治的非感染性、非坏死性巩膜炎中发挥作用，主要是通过减轻炎症和减少同时使用的皮质类固醇剂量。
Zotero 插件